Andre C. Schuh
Toronto, ON M5S1A8, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications
Controversies in the Management of AML in Older Patients: A Canadian Perspective.
Journal: Current oncology (Toronto, Ont.)
Published: May 07, 2026
Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus.
Journal: Current oncology (Toronto, Ont.)
Published: May 07, 2026
Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.
Journal: Current oncology (Toronto, Ont.)
Published: January 06, 2026
High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.
Journal: Leukemia
Published: October 13, 2025
What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 18, 2025
Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis.
Journal: British journal of haematology
Published: August 28, 2025
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.
Journal: The Lancet. Haematology
Published: May 23, 2025
Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summary.
Journal: Expert review of hematology
Published: May 21, 2025
2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia.
Journal: British journal of haematology
Published: May 05, 2025
Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.
Journal: Blood cancer journal
Published: April 21, 2025
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial.
Journal: The Lancet. Haematology
Published: April 10, 2025
Last Updated: 09/26/2026